Treating Protein C Deficiency

SLU ID 14-016 | Thrombin-Thrombomodulin chimera as a protein C activator

Background

Protein C deficiency is a rare genetic disorder that increases the risk of developing abnormal blood clots. The condition can be mild to severe. Those with the condition have an increased risk for deep vein thrombosis and pulmonary embolism.

Overview

Researchers at Saint Louis University have identified thrombin-thrombomodulin fusion proteins, vectors, and host cells that act as protein C activators. They have also developed methods for preparing the thrombin-thrombomodulin fusion proteins.

Benefits

The potential benefits of this technology include:

• Increasing the specificity of treatments

• Minimizing production costs

• Minimizing the risk of developing deep vein thrombosis

• Minimizing the risk of developing a pulmonary embolism

Applications

The potential applications of this technology include:

• treating protein C deficiency

Opportunity

Saint Louis University is seeking a partner to further develop and commercialize this technology.